Follow the science.
Find your starting point.

Reference updated · 2026-10-28

5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide. Cell and obese-mouse findings support metabolic research, but human weight-loss efficacy, pharmacokinetics, dosing and long-term safety remain unestablished. Marketed in the wellness and longevity space for metabolism and fat loss, but not FDA-approved for any use

Reference updated · 2026-10-28

Abaloparatide is a bone-forming PTHrP analog used for osteoporosis at high fracture risk. Its fracture and bone-density findings, approved use and calcium-related risks should be read alongside the distinction from teriparatide. FDA-approved peptide injection

Reference updated · 2026-10-28

Acetyl tetrapeptide-5, marketed as Eyeseryl, is a topical cosmetic ingredient for the appearance of under-eye puffiness. Its evidence is primarily manufacturer-associated rather than independently replicated clinical research. Cosmetic ingredient rather than a drug, so does not require FDA approval

Reference updated · 2026-10-28

Placebo-controlled trials support the regulated implant for EPP; they do not establish benefit or safety for unregulated tanning injections. Scenesse implant is FDA-approved for adult EPP; cosmetic tanning injections are not approved.

Reference updated · 2026-10-28

The HARMONY program supports diabetes efficacy and cardiovascular benefit in a defined high-risk population; the product was later commercially withdrawn. FDA-approved in 2014, but Tanzeum was withdrawn from sale in 2018 for commercial reasons.

Reference updated · 2026-10-28

Early Phase 1/2a human data show dose-related weight changes; substantial discontinuation and limited follow-up constrain interpretation. Investigational; no regulatory approval in the published account.

Reference updated · 2026-10-28

Angiotensin II is an eight-amino-acid blood-pressure hormone. Its synthetic medicine, Giapreza, is a closely monitored hospital infusion for septic or other distributive shock, with thrombosis an important safety concern. FDA-approved peptide, sold as Giapreza, given as an intravenous infusion in intensive care

Reference updated · 2026-10-28

Human obesity efficacy was not established; experimental cartilage findings and later pain programs remain separate evidence contexts. Not FDA-approved; withdrawn 503A nomination and WADA restrictions apply.

Reference updated · 2026-10-28

Apraglutide is an investigational long-acting GLP-2 analog for short bowel syndrome with intestinal failure. Positive support-reduction findings coexist with a requirement for another confirmatory Phase 3 study. Investigational peptide, not approved by the FDA

Source checked · 2026-10-27

Cibinetide is an 11-amino-acid EPO-derived peptide. Small sarcoidosis trials show selected nerve-fiber signals but not consistent between-group pain benefit; serious adverse events and short follow-up limit safety conclusions. US product records not fully adjudicated.

Reference updated · 2026-10-28

Argireline is a topical cosmetic hexapeptide with modest and inconsistent wrinkle-study findings. Delivery through skin, finished-formulation composition and active-peptide concentration matter, and equivalence to injected botulinum toxin is not established. Cosmetic ingredient rather than a drug, so does not require FDA approval

Reference updated · 2026-10-28

Bacitracin is a mixture of cyclic peptide antibiotics used mainly on the skin. Its topical and eye-product roles are distinct from the injectable form withdrawn in the United States because of serious kidney toxicity. FDA-approved polypeptide antibiotic, sold over the counter as a topical ointment for minor wounds

Reference updated · 2026-10-28

A negative randomized Phase 3 trial outweighs the earlier uncontrolled response signal. Investigational and unapproved; development effectively ended.

Reference updated · 2026-10-28

Bivalirudin is a short-acting direct thrombin inhibitor used during coronary interventions. Its hospital-only anticoagulation benefits must be balanced against bleeding and an early stent-thrombosis signal. FDA-approved peptide anticoagulant, sold as Angiomax, given intravenously in the hospital

Reference updated · 2026-10-28

BPC-157 is a synthetic gastric-protein-related pentadecapeptide with extensive animal repair research and limited, low-certainty human reports. Its history, preliminary clinical signals, safety unknowns and unapproved status belong alongside the mechanistic interest. Not approved by the FDA for any use

Reference updated · 2026-10-28

Peer-reviewed support is primarily preclinical; positive human findings are company topline announcements rather than controlled peer-reviewed efficacy reports. Investigational; no approved use.

Reference updated · 2026-10-28

Cagrilintide is Novo Nordisk’s long-acting amylin analog. Research includes weight-loss studies of the molecule alone and its combination with semaglutide, CagriSema; neither research dosing nor an application establishes an approved standalone product. Investigational peptide, not approved by the FDA or any regulator

Reference updated · 2026-10-28

CagriSema combines cagrilintide with semaglutide in a weekly investigational treatment. Its obesity and diabetes studies show substantial benefit, while its direct tirzepatide comparison, different estimands and pending regulatory status remain essential context. Investigational combination peptide, not yet approved (under FDA review as of 2026)

Reference updated · 2026-10-28

PROOF showed a modest vertebral-fracture benefit at 200 IUdaily; long-term benefit-risk concerns restrict routine osteoporosis use. FDA-approved product-specific osteoporosis, Paget disease and hypercalcemia uses.

Reference updated · 2026-10-28

Antioxidant and anti-glycation findings are mainly laboratory and ex-vivo evidence; standalone human appearance trials are inadequate. Cosmetic ingredient, not an approved therapeutic drug; ordinary cosmetic ingredients do not undergo drug-style FDA preapproval.

Reference updated · 2026-10-28

Condition-specific recovery signals coexist with neutral mortality and possible nonfatal serious harm; population and endpoint affect interpretation. Used under foreign authorizations; not FDA-approved or available through routine US compounding.

Reference updated · 2026-10-28

Randomized trials and meta-analyses support LH-surge prevention during ovarian stimulation and lower OHSS risk than long agonist protocols. Cetrotide is FDA-approved for prevention of premature LH surges during controlled ovarian stimulation.

Source checked · 2026-10-26

A related CJC reference route, with long-acting hormone data and unresolved product-form questions.

Reference updated · 2026-10-28

Short healthy-adult GH/IGF-1 and pharmacokinetic studies of DAC-related material; clinical wellness outcomes remain unestablished. No FDA-approved CJC-1295 product; nominated-but-withdrawn compounding status is not approval.